Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $826.59 Average PT from Analysts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has received an average recommendation of “Moderate Buy” from the twenty-six analysts that are presently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a hold recommendation, sixteen have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $826.5909.

REGN has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, March 27th. Sanford C. Bernstein decreased their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. Barclays dropped their price objective on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Morgan Stanley boosted their target price on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Finally, Truist Financial dropped their price target on Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating on the stock in a research report on Thursday, April 30th.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the sale, the senior vice president directly owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This represents a 32.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 3,874 shares of company stock valued at $3,013,262. 6.97% of the stock is currently owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Norges Bank bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $1,012,296,000. Price T Rowe Associates Inc. MD grew its stake in shares of Regeneron Pharmaceuticals by 142.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after acquiring an additional 1,144,887 shares in the last quarter. Nuveen LLC raised its holdings in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after purchasing an additional 835,240 shares during the last quarter. Dodge & Cox lifted its position in shares of Regeneron Pharmaceuticals by 18.9% in the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock worth $2,558,804,000 after purchasing an additional 724,562 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in Regeneron Pharmaceuticals by 8,620.0% during the fourth quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company’s stock worth $512,881,000 after purchasing an additional 656,845 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 1.7%

NASDAQ:REGN opened at $709.10 on Friday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $821.11. The firm has a market capitalization of $74.97 billion, a price-to-earnings ratio of 17.28, a PEG ratio of 1.61 and a beta of 0.30. The business’s 50-day moving average price is $752.68 and its two-hundred day moving average price is $740.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same period in the previous year, the company earned $8.22 EPS. On average, equities analysts expect that Regeneron Pharmaceuticals will post 36.85 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.